Phg.Bk
Pharmaceutical company operating in the healthcare facilities and services industry, generating revenue primarily through pharmaceutical products and services.
Business. Pharmaceutical company operating in the healthcare facilities and services industry, generating revenue primarily through pharmaceutical products and services.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Pharmaceutical company operating in the healthcare facilities and services industry, generating revenue primarily through pharmaceutical products and services.
The company maintains a strong liquidity position, with a current ratio of 4.93, indicating a robust ability to meet short-term obligations. The liquidity_fpt metric further supports this, showing a high level of cash and equivalents at 337.22 million THB, which is a significant portion of total assets. This liquidity is complemented by a free cash flow of 195.66 million THB, suggesting the company has ample cash to reinvest or return to shareholders.
Profitability metrics indicate a healthy return on equity of 13.99% and a return on assets of 11.88%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing well relative to its peers. The operating income of 388.03 million THB and net income of 309.47 million THB further underscore the company's profitability.
The company's revenue is concentrated in the pharmaceutical segment, with no disclosed geographic diversification in the provided data. This concentration may pose a risk if the pharmaceutical market experiences a downturn, as the company's performance is closely tied to this single segment.
Looking at the growth trajectory, the company has demonstrated consistent revenue growth, with a total revenue of 2.51 billion THB. The outlook for the current fiscal year is positive, with expected growth in revenue and profitability. The company's capital expenditure of -72.14 million THB indicates a reduction in capital spending, which may be a strategic move to preserve cash.
Risk factors are minimal, with a low liquidity risk and no immediate dilution concerns. The company's debt-to-equity ratio is 0.0, indicating no long-term debt, which reduces financial risk. The absence of dilution flags suggests that the company is not currently issuing new shares, which is favorable for existing shareholders.
Recent events, as reflected in the financial data, show a stable and growing company with strong cash flow and profitability. The company's financial health is supported by its strong liquidity and profitability metrics, which are key indicators of its operational efficiency and financial stability.
- The company has a strong liquidity position with a current ratio of 4.93 and significant cash reserves.
- Profitability is robust, with a return on equity of 13.99% and a return on assets of 11.88%.
- The company's revenue is concentrated in the pharmaceutical segment, which may pose a risk if the market experiences a downturn.
- Growth is expected to continue, supported by strong cash flow and profitability.
- The company has no long-term debt, reducing financial risk and indicating a conservative capital structure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PHG.BK Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Ranjit YamsaardChief Executive Officer, Executive Director